COEP News and Press, Coeptis Therapeutics Inc From 06/23/22

The biotech indices have fallen considerably. Many biotechs are trading with negative enterprise values despite unprecedented innovation in the biotech industry. I-Mab is headed for commercialization with enough cash to carry then into 2025 with multiple products hitting the ...

Coeptis Therapeutics Enters into Exclusive Option Agreement with University of Pittsburgh for Rights to CAR-T Technologies Designed to Target Multiple Cancer Indications, Including Hematologic and Solid Tumors PR Newswire Option agreement comprises three technologies a...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Coeptis Therapeutics (OTCPK:COEP) plans to merge with SPAC Bull Horn Holdings (BHSE) and uplist its shares to Nasdaq. The deal is expected to close in Q3, subject to shareholder approval by both companies. COEP shareholders will receive equity valued at around $175M in Bull Horn, subject to a...

Coeptis Therapeutics, Inc. and Bull Horn Holdings Corp. Announce Merger Agreement PR Newswire Transaction expected to accelerate Coeptis' ability to progress its innovative cell therapy platforms for cancer David Mehalick of Coeptis to serve as Chief Execut...

FORT COLLINS, Colo., April 13, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the Company has agreed to ...

Coeptis Therapeutics (OTCPK:COEP) signed an agreement that gives it the right to acquire Statera Biopharma's (NASDAQ:STAB) toll-like receptor 5 (TLR5) agonist platform, including entolimod which is being developed to treat acute radiation syndrome. Under the agreement, Coeptis will ...

Coeptis Therapeutics Announces Intent to Acquire TLR5 Agonist Platform, Including Clinical-Stage Asset Entolimod, from Statera Biopharma PR Newswire Entolimod is currently in clinical development as a potential treatment for acute radiation syndrome with additional pre...

Coeptis Therapeutics Establishes Scientific Advisory Board to Advance Cell Therapy Product Development Newly formed Scientific Advisory Board includes three members from the prestigious Karolinska Institutet (KI) PR Newswire WEXFORD, Pa. , Jan. 20, 2022 /PRNe...

Coeptis Therapeutics Partners with VyGen-Bio, Inc. to Co-develop Two Assets Designed to Improve the Treatment of CD38-Related Cancers Technologies include CD38-GEAR-NK, a cell therapy technology, and CD38-Diagnostic, an in vitro diagnostic PR Newswire WEXFORD, Pa. ...